Form 4 holding
Director
ARVINAS, INC.
- Security class
- Common Stock
- Shares / value
- 96,021
- Estimated value
- $1,287,017
- Report date
- 06 Mar 2026
- Price
- $13.40
- Ownership
- Direct
Briggs Morrison
Insider Reports History
- Reporting-owner location
- Waltham, MA
- Latest reporting-owner signature
- /s/ Jared Freedberg, as attorney-in-fact for Briggs Morrison
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Briggs Morrison
Form 4 holding
Director
Syndax Pharmaceuticals Inc
- Security class
- Common Stock
- Shares / value
- 34,836
- Estimated value
- $636,283
- Report date
- 07 Feb 2024
- Price
- $18.27
- Ownership
- Direct
Form 4 holding
Director
CRISPR Therapeutics AG
- Security class
- Common Shares
- Shares / value
- 5,209
- Estimated value
- $195,806
- Report date
- 05 Jun 2025
- Price
- $37.59
- Ownership
- Direct
Form 4 holding
Director
ARVINAS, INC.
- Security class
- Stock Option (right to buy)
- Shares / value
- 23,105
- Estimated value
- $145,120
- Report date
- 25 Jun 2025
- Price
- $16.00
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Repare Therapeutics Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 27,200
- Estimated value
- Report date
- 17 Jun 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
Form 4 holding
Director
Werewolf Therapeutics, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 27,000
- Estimated value
- Report date
- 12 Jun 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Carisma Therapeutics Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 19,350
- Estimated value
- Report date
- 26 Jun 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
CRISPR Therapeutics AG
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 13,000
- Estimated value
- Report date
- 05 Jun 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
Form 4 holding
Director
Syndax Pharmaceuticals Inc
- Security class
- Stock Options (Right to buy)
- Shares / value
- 0
- Estimated value
- Report date
- 09 Aug 2023
- Price
- $25.84
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Briggs Morrison
4
ARVN
ARVINAS, INC.
- Report period
- 06 Mar 2026
- Transactions
- 1
- Transaction value
- +$268,070
- Accepted by SEC
- 09 Mar 2026, 16:05
- Role
- Director
- Next action
- Open filing details
4
ARVN
ARVINAS, INC.
- Report period
- 22 Sep 2025
- Transactions
- 1
- Transaction value
- +$227,010
- Accepted by SEC
- 24 Sep 2025, 09:16
- Role
- Director
- Next action
- Open filing details
4
ARVN
ARVINAS, INC.
- Report period
- 25 Jun 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 27 Jun 2025, 21:14
- Role
- Director
- Next action
- Open filing details
4
HOWL
Werewolf Therapeutics, Inc.
- Report period
- 12 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2025, 16:10
- Role
- Director
- Next action
- Open filing details
3/A
CRSP
CRISPR Therapeutics AG
- Report period
- 05 Jun 2025
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 10 Jun 2025, 17:31
- Role
- Director
- Next action
- Open filing details
4
CRSP
CRISPR Therapeutics AG
- Report period
- 05 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 06 Jun 2025, 17:30
- Role
- Director
- Next action
- Open filing details
4
CARM
Carisma Therapeutics Inc.
- Report period
- 26 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 27 Jun 2024, 16:54
- Role
- Director
- Next action
- Open filing details
4
RPTX
Repare Therapeutics Inc.
- Report period
- 17 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 20 Jun 2024, 16:35
- Role
- Director
- Next action
- Open filing details
4
ARVN
ARVINAS, INC.
- Report period
- 29 May 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 31 May 2024, 17:51
- Role
- Director
- Next action
- Open filing details
4
HOWL
Werewolf Therapeutics, Inc.
- Report period
- 24 May 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 24 May 2024, 19:49
- Role
- Director
- Next action
- Open filing details
4
SNDX
Syndax Pharmaceuticals Inc
- Report period
- 07 Feb 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 09 Feb 2024, 16:04
- Role
- Director
- Next action
- Open filing details
4
SNDX
Syndax Pharmaceuticals Inc
- Report period
- 09 Aug 2023
- Transactions
- 3
- Transaction value
- -$501,864
- Accepted by SEC
- 10 Aug 2023, 06:50
- Role
- Director
- Next action
- Open filing details
4
SNDX
Syndax Pharmaceuticals Inc
- Report period
- 10 Jul 2023
- Transactions
- 3
- Transaction value
- -$614,529
- Accepted by SEC
- 11 Jul 2023, 09:23
- Role
- Director
- Next action
- Open filing details
4
HOWL
Werewolf Therapeutics, Inc.
- Report period
- 21 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 23 Jun 2023, 17:07
- Role
- Director
- Next action
- Open filing details
4
ARVN
ARVINAS, INC.
- Report period
- 15 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 20 Jun 2023, 17:27
- Role
- Director
- Next action
- Open filing details
4
SNDX
Syndax Pharmaceuticals Inc
- Report period
- 09 Jun 2023
- Transactions
- 6
- Transaction value
- -$714,634
- Accepted by SEC
- 09 Jun 2023, 17:32
- Role
- Director
- Next action
- Open filing details
4
RPTX
Repare Therapeutics Inc.
- Report period
- 08 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 12 Jun 2023, 16:27
- Role
- Director
- Next action
- Open filing details
4
CARM
Carisma Therapeutics Inc.
- Report period
- 06 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 08 Jun 2023, 18:11
- Role
- Director
- Next action
- Open filing details
4
SNDX
Syndax Pharmaceuticals Inc
- Report period
- 09 May 2023
- Transactions
- 3
- Transaction value
- -$794,263
- Accepted by SEC
- 10 May 2023, 16:11
- Role
- Director
- Next action
- Open filing details
4
SNDX
Syndax Pharmaceuticals Inc
- Report period
- 10 Apr 2023
- Transactions
- 3
- Transaction value
- -$695,022
- Accepted by SEC
- 12 Apr 2023, 16:03
- Role
- Director
- Next action
- Open filing details
4
SNDX
Syndax Pharmaceuticals Inc
- Report period
- 13 Mar 2023
- Transactions
- 3
- Transaction value
- -$853,465
- Accepted by SEC
- 14 Mar 2023, 16:42
- Role
- President, Head of R&D, Director
- Next action
- Open filing details
4
CARM
Carisma Therapeutics Inc.
- Report period
- 07 Mar 2023
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 09 Mar 2023, 20:21
- Role
- Director
- Next action
- Open filing details
3
CARM
Carisma Therapeutics Inc.
- Report period
- 07 Mar 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 09 Mar 2023, 20:04
- Role
- Director
- Next action
- Open filing details
4
SNDX
Syndax Pharmaceuticals Inc
- Report period
- 06 Feb 2023
- Transactions
- 3
- Transaction value
- -$1,080,700
- Accepted by SEC
- 08 Feb 2023, 15:49
- Role
- President, Head of R&D, Director
- Next action
- Open filing details
4
SNDX
Syndax Pharmaceuticals Inc
- Report period
- 02 Feb 2023
- Transactions
- 1
- Transaction value
- +$913,600
- Accepted by SEC
- 03 Feb 2023, 16:02
- Role
- President, Head of R&D, Director
- Next action
- Open filing details
4
SNDX
Syndax Pharmaceuticals Inc
- Report period
- 19 Sep 2022
- Transactions
- 6
- Transaction value
- -$2,123,587
- Accepted by SEC
- 21 Sep 2022, 16:18
- Role
- President, Head of R&D, Director
- Next action
- Open filing details
4
SNDX
Syndax Pharmaceuticals Inc
- Report period
- 14 Sep 2022
- Transactions
- 12
- Transaction value
- -$4,396,277
- Accepted by SEC
- 16 Sep 2022, 17:34
- Role
- President, Head of R&D, Director
- Next action
- Open filing details
4
SNDX
Syndax Pharmaceuticals Inc
- Report period
- 01 Jul 2022
- Transactions
- 3
- Transaction value
- -$734,927
- Accepted by SEC
- 05 Jul 2022, 16:09
- Role
- President, Head of R&D, Director
- Next action
- Open filing details
4
ARVN
ARVINAS, INC.
- Report period
- 16 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 21 Jun 2022, 20:00
- Role
- Director
- Next action
- Open filing details
4
HOWL
Werewolf Therapeutics, Inc.
- Report period
- 01 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 03 Jun 2022, 16:41
- Role
- Director
- Next action
- Open filing details
4
RPTX
Repare Therapeutics Inc.
- Report period
- 13 May 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 16 May 2022, 19:25
- Role
- Director
- Next action
- Open filing details
4
ARVN
ARVINAS, INC.
- Report period
- 14 Apr 2022
- Transactions
- 5
- Transaction value
- -$1,133,608
- Accepted by SEC
- 18 Apr 2022, 21:00
- Role
- Director
- Next action
- Open filing details
4/A
SNDX
Syndax Pharmaceuticals Inc
- Report period
- 01 Apr 2022
- Transactions
- 4
- Transaction value
- +$530,446
- Accepted by SEC
- 13 Apr 2022, 16:09
- Role
- President, Head of R&D, Director
- Next action
- Open filing details
4
SNDX
Syndax Pharmaceuticals Inc
- Report period
- 02 Feb 2022
- Transactions
- 1
- Transaction value
- +$2,526,400
- Accepted by SEC
- 03 Feb 2022, 16:32
- Role
- President, Head of R&D, Director
- Next action
- Open filing details
4
ARVN
ARVINAS, INC.
- Report period
- 14 Jan 2022
- Transactions
- 6
- Transaction value
- -$1,115,013
- Accepted by SEC
- 19 Jan 2022, 20:00
- Role
- Director
- Next action
- Open filing details
4
SNDX
Syndax Pharmaceuticals Inc
- Report period
- 17 Dec 2021
- Transactions
- 3
- Transaction value
- -$319,920
- Accepted by SEC
- 20 Dec 2021, 17:44
- Role
- Chief Executive Officer, Director
- Next action
- Open filing details
4
SNDX
Syndax Pharmaceuticals Inc
- Report period
- 17 Sep 2021
- Transactions
- 6
- Transaction value
- -$904,771
- Accepted by SEC
- 21 Sep 2021, 16:35
- Role
- Chief Executive Officer, Director
- Next action
- Open filing details
4
ARVN
ARVINAS, INC.
- Report period
- 08 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 10 Jun 2021, 20:00
- Role
- Director
- Next action
- Open filing details
4
RPTX
Repare Therapeutics Inc.
- Report period
- 13 May 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 14 May 2021, 16:53
- Role
- Director
- Next action
- Open filing details